Skye Bioscience, Inc. Common Stock
About
Skye Bioscience, Inc. Common Stock (NASDAQ:SKYE) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 7 2026
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
Apr 2 2026
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
Mar 10 2026
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Mar 5 2026
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
Feb 17 2026
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
Financials
Revenue
$0
Market Cap
$24.23 M
EPS
-1.44